While it’s the biggest, Biogen is not the only Bay State biotech presenting promising data for an Alzheimer’s drug this morning. The small Lexington-based biotech, Alzheon, reported promising data at the same conference in France from an early-stage trial of its pill to inhibit the formation of amyloid clumps in the brain.